Clarithromycin use and risk of death in patients with ischemic heart disease.

Abstract

OBJECTIVES:

To examine whether treatment with clarithromycin was associated with an increased risk of death in patients with preexisting ischemic heart disease (IHD).

METHODS:

Employing nationwide registers, all patients with IHD events from 1997 to 2007 who subsequently claimed prescriptions for dual antibiotic treatment for eradication treatment were identified. The primary endpoint was all-cause mortality.

RESULTS:

The study included 214,330 individuals with IHD; 5,265 (2.5 %) of these claimed prescriptions for dual antibiotics. Compared with IHD patients not undergoing eradication therapy, no increase in the risk of all-cause mortality was demonstrated (HR 1.02; 95% CI 0.84-1.23, p = 0.87) after 5 years.

CONCLUSIONS:

The use of clarithromycin in the setting of eradication treatment for Helicobacter pylori in patients with IHD was not associated with an increased risk of death.

• Authors: Søren Skøtt Andersen, Morten Lock Hansen, Mette Lykke Norgaard, Fredrik Folke, Emil Loldrup Fosbøl, Steen Z Abildstrøm, Jakob Raunsø, Mette Madsen, Lars Køber, Gunnar H Gislason, Christian Torp-Pedersen
• Journal: Cardiology (Cardiology) Vol. 116 Issue 2 Pg. 89-97 ( 2010) ISSN: 1421-9751 [Electronic] Switzerland
• PMID: 20523043 (Publication Type: Journal Article)
• Copyright: Copyright 2010 S. Karger AG, Basel.

Chemical References

• Anti-Bacterial Agents
• Clarithromycin

Topics

• Adult
• Aged
• Anti-Bacterial Agents (administration & dosage, adverse effects)
• Chlamydophila Infections (drug therapy, mortality)
• Chlamydophila pneumoniae
• Clarithromycin (administration & dosage, adverse effects)
• Female
• Helicobacter Infections (drug therapy, mortality)
• Helicobacter pylori
• Hospital Mortality
• Humans
• Male
• Middle Aged
• Myocardial Ischemia (mortality)
• Risk Factors